Bryant D. Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bryant D. Miller has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Martin S. Taylor
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
133 shared publications - John LaCava
European Research Institute for the Biology of Ageing, University Medical Center, Groningen, Netherlands
132 shared publications - Kathleen H. Burns
Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
132 shared publications - Michael P. Rout
Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065
132 shared publications - Jennifer E. Fairman
Johns Hopkins University School of Medicine, Baltimore, USA
131 shared publications - Wen-Chih Cheng
Department of Pathology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
131 shared publications
Latest Publications
- Top Cited Papers
- 5 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6789) , eadv7111
Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2
The mechanistic target of rapamycin (mTOR) protein kinase forms two multiprotein complexes, mTORC1 and mTORC2, that function in distinct signaling pathways. mTORC1 is regulated by nutrients, and mTORC2 is a central node in phosphoinositide-3 kinase (PI3K) and small guanosine triphosphate Ras signaling networks commonly deregulated in cancer and diabetes. Although mTOR phosphorylates many substrates in vitro, in cells, mTORC1 and mTORC2 have high specificity: mTORC2 phosphorylates the protein kinases Akt and PKC, but not closely related kinases that are mTORC1 substrates. To understand how mTORC2 recognizes substrates, we created semisynthetic probes to trap the mTORC2 :: Akt complex and determine its structure. Whereas most protein kinases recognize amino acids adjacent to the phosphorylation site, local sequence contributes little to substrate recognition by mTORC2. Instead, the specificity determinants were secondary and tertiary structural elements of Akt that bound the mTORC2 component mSin1 distal to the mTOR active site and were conserved among at least 18 related substrates. These results reveal how mTORC2 recognizes its canonical substrates and may enable the design of mTORC2-specific inhibitors.
- 5 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6789) , eadv7111
Top Cited PapersStructural basis for the recruitment and selective phosphorylation of Akt by mTORC2
The mechanistic target of rapamycin (mTOR) protein kinase forms two multiprotein complexes, mTORC1 and mTORC2, that function in distinct signaling pathways. mTORC1 is regulated by nutrients, and mTORC2 is a central node in phosphoinositide-3 kinase (PI3K) and small guanosine triphosphate Ras signaling networks commonly deregulated in cancer and diabetes. Although mTOR phosphorylates many substrates in vitro, in cells, mTORC1 and mTORC2 have high specificity: mTORC2 phosphorylates the protein kinases Akt and PKC, but not closely related kinases that are mTORC1 substrates. To understand how mTORC2 recognizes substrates, we created semisynthetic probes to trap the mTORC2 :: Akt complex and determine its structure. Whereas most protein kinases recognize amino acids adjacent to the phosphorylation site, local sequence contributes little to substrate recognition by mTORC2. Instead, the specificity determinants were secondary and tertiary structural elements of Akt that bound the mTORC2 component mSin1 distal to the mTOR active site and were conserved among at least 18 related substrates. These results reveal how mTORC2 recognizes its canonical substrates and may enable the design of mTORC2-specific inhibitors.
- Open Access
- 29 November 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (1) , 110994
Rapid DNA cleavage by the LINE-1 endonuclease proximal to DNA ends and at mismatches
- 29 November 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (1) , 110994
Open AccessRapid DNA cleavage by the LINE-1 endonuclease proximal to DNA ends and at mismatches
- 19 July 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (11) , 1894-1905
Protein semisynthesis reveals plasticity in HECT E3 ubiquitin ligase mechanisms
Lys ubiquitination is catalysed by E3 ubiquitin ligases and is central to the regulation of protein stability and cell signalling in normal and disease states. There are gaps in our understanding of E3 mechanisms, and here we use protein semisynthesis, chemical rescue, microscale thermophoresis and other biochemical approaches to dissect the role of catalytic base/acid function and conformational interconversion in HECT-domain E3 catalysis. We demonstrate that there is plasticity in the use of the terminal side chain or backbone carboxylate for proton transfer in HECT E3 ubiquitin ligase reactions, with yeast Rsp5 orthologues appearing to be possible evolutionary intermediates. We also show that the HECT-domain ubiquitin covalent intermediate appears to eject the E2 conjugating enzyme, promoting catalytic turnover. These findings provide key mechanistic insights into how protein ubiquitination occurs and provide a framework for understanding E3 functions and regulation.
- 19 July 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (11) , 1894-1905
Protein semisynthesis reveals plasticity in HECT E3 ubiquitin ligase mechanisms
Lys ubiquitination is catalysed by E3 ubiquitin ligases and is central to the regulation of protein stability and cell signalling in normal and disease states. There are gaps in our understanding of E3 mechanisms, and here we use protein semisynthesis, chemical rescue, microscale thermophoresis and other biochemical approaches to dissect the role of catalytic base/acid function and conformational interconversion in HECT-domain E3 catalysis. We demonstrate that there is plasticity in the use of the terminal side chain or backbone carboxylate for proton transfer in HECT E3 ubiquitin ligase reactions, with yeast Rsp5 orthologues appearing to be possible evolutionary intermediates. We also show that the HECT-domain ubiquitin covalent intermediate appears to eject the E2 conjugating enzyme, promoting catalytic turnover. These findings provide key mechanistic insights into how protein ubiquitination occurs and provide a framework for understanding E3 functions and regulation.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 23 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Targeted proteomics analysis of patient plasma.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 23 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Targeted proteomics analysis of patient plasma.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 29 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Schoenfeld Tests and Residuals.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 29 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Schoenfeld Tests and Residuals.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Analysis of circulating ORF1p levels in extracellular vesicles (EVs) fractions.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Analysis of circulating ORF1p levels in extracellular vesicles (EVs) fractions.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 27 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Kaplan-Meier Survival Analysis by ORF1p.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 27 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Kaplan-Meier Survival Analysis by ORF1p.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Genomics analysis of lung cancer patient cohort.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Genomics analysis of lung cancer patient cohort.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 18 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Second round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 18 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Second round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.
- Open Access
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 19 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Assay validation for second-generation ORF1p Simoa assays.
- 20 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 19 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
Assay validation for second-generation ORF1p Simoa assays.